Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Galmed Pharmaceutica (GLMD)

Galmed Pharmaceutica (GLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,911
  • Shares Outstanding, K 5,045
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,910 K
  • 60-Month Beta 0.87
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.13
Trade GLMD with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.26
  • Most Recent Earnings $-0.98 on 04/04/24
  • Latest Earnings Date 06/06/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -2.25
  • Growth Rate Est. (year over year) +44,500.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3000 +24.27%
on 03/20/24
0.4400 -15.27%
on 04/10/24
+0.0596 (+19.03%)
since 03/19/24
3-Month
0.3000 +24.27%
on 03/20/24
0.4688 -20.48%
on 02/13/24
+0.0357 (+10.59%)
since 01/19/24
52-Week
0.2600 +43.38%
on 11/21/23
7.8000 -95.22%
on 05/05/23
-4.5787 (-92.47%)
since 04/19/23

Most Recent Stories

More News
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

GALT : 3.37 (-0.30%)
GLMD : 0.3728 (-1.56%)
VKTX : 63.42 (-1.93%)
ETNB : 9.08 (+2.25%)
IVA : 3.33 (-3.48%)
SGMT : 4.01 (+1.01%)
TERN : 4.56 (-0.65%)
NVO : 122.71 (-0.03%)
IQV : 228.09 (+0.40%)
MDGL : 212.04 (-4.60%)
Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...

GLMD : 0.3728 (-1.56%)
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

/PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...

GLMD : 0.3728 (-1.56%)
Galmed Pharmaceuticals: Q2 Earnings Snapshot

Galmed Pharmaceuticals: Q2 Earnings Snapshot

GLMD : 0.3728 (-1.56%)
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...

GLMD : 0.3728 (-1.56%)
Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...

GLMD : 0.3728 (-1.56%)
Galmed Pharmaceuticals: Q1 Earnings Snapshot

Galmed Pharmaceuticals: Q1 Earnings Snapshot

GLMD : 0.3728 (-1.56%)
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...

GLMD : 0.3728 (-1.56%)
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a biopharmaceutical company focused on the development of Aramchol and...

GLMD : 0.3728 (-1.56%)
Galmed Pharmaceuticals: Q3 Earnings Snapshot

Galmed Pharmaceuticals: Q3 Earnings Snapshot

GLMD : 0.3728 (-1.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel.

See More

Key Turning Points

3rd Resistance Point 0.3860
2nd Resistance Point 0.3823
1st Resistance Point 0.3775
Last Price 0.3728
1st Support Level 0.3690
2nd Support Level 0.3653
3rd Support Level 0.3605

See More

52-Week High 7.8000
Fibonacci 61.8% 4.9197
Fibonacci 50% 4.0300
Fibonacci 38.2% 3.1403
Last Price 0.3728
52-Week Low 0.2600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar